In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on VolitionRX (VNRX), with a price target of $6. The company’s shares opened today at $3.40, close to its 52-week high of $3.45.
McCarthy commented:
“VolitionRx reported 4Q18 with a net loss of ($4.1M). The company ended the period with $13.4M in cash, which does not include an additional $6.7M in warrant exercises in 1Q19. The company has maintained a cash burn of ~ $3.9M, so we estimate VolitionRx has runway into 1H20.”
According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.9% and a 32.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inovio Pharmaceuticals, and Vertex Pharmaceuticals.
VolitionRX has an analyst consensus of Moderate Buy, with a price target consensus of $6.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.45 and a one-year low of $1.44. Currently, VolitionRX has an average volume of 106.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid.